Comparing two doses of dexmedetomedine against lignocaine in decreasing the stress response to laryngoscopy and intubation

Recruiting

• Registration Number: CTRI/2020/07/026647
• Lead Sponsor: Kidwai memorial insitute of Oncology

Brief Summary

Hemodynamic stress response or the Pressor response to laryngoscopy  and intubation is very detrimental in cancer patients as they are weak due to the malignancy itself and due to concurrent treatment like Radiotherapy and chemotherapeutic drugs many of which have major side effects

There is always a need for an agent to overcome this response without any adverse effects



Dexmedetomidine is an alpha 2 adrenoceptor agonist which has the capability to totally blunt the hemodynamic stress response during laryngoscopy and intubation. But, Higher loading doses have known to cause side effects like Bradycardia and Hypotension which maybe counter productive in cancer patients as it leads to other complications that may alter intraoperative management and thereby postoperative recovery.. Hence if lower doses of dexmedetomidine can blunt this hemodynamic response without the side effects of bradycardia and hypotension, it would be of great help in the intraoperative management and early post op recovery of the cancer patient



Lignocaine is a local anesthetic which has been known to reduce the hemodynamic stress response to laryngoscopy and intubation but not blunt it completely. We want to give an active drug instead of a placebo as it may be of some benefit to the already ailing cancer patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-20
• Last Update Posted: 2021-03-19

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: All
• Target Recruitment: 210

Inclusion Criteria

Patients consenting for study American society of anesthesiologists (ASA) status 1 and 2 Patients undergoing elective oncosurgeries.

Exclusion Criteria

Patient refusal History of allergy to study drug Patients on Calcium channel blockers, beta blockers, ACE inhibitors Anticipated difficult airway More than two attempts at intubation History of Cerebrovascular accident, Ischemic Heart disease, Chronic Obstructive lung disease, Chronic Hypertension Impaired Renal function tests Impaired Liver function tests.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
No increase in Heart rate, Systolic blood pressure, Diastolic blood pressure, Mean arterial pressure with the intervention drug as compared to the baseline	Baseline values | Before induction | before intubation | 1 min after intubation | 3 mins after intubation | 5 mins after intubation | 10 mins after intubation

Secondary Outcome Measures

Name	Time	Method
Development of Hypotension and Bradycardia with Study drug	Baseline before study drug administration

Trial Locations

Locations (1)

Kidwai Memorial Institute of Oncology; 🇮🇳 Bangalore, KARNATAKA, India

Kidwai Memorial Institute of Oncology

🇮🇳Bangalore, KARNATAKA, India

Dr Nevin Philip Mancha

Principal investigator

9655747324

philvin1991@gmail.com